Literature DB >> 8169854

Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury.

M J Mangino1, M K Murphy, C B Anderson.   

Abstract

This study was designed to characterize the role of arachidonate 5-lipoxygenase metabolism during experimental intestinal ischemia-reperfusion (I/R) injury. Canines were subjected to 3 hr of intestinal ischemia followed by 1 hr of normobaric reperfusion. Intestinal ischemia followed by 1 hr of normobaric reperfusion. Intestinal mucosal leukotriene B4 and leukotriene C4 synthesis tripled after ischemia and ischemia-reperfusion, relative to non-ischemic intestinal mucosa. The flux of fluid and protein from the capillary to the lumen also increased 3-fold after I/R. The selective 5-lipoxygenase synthesis inhibitor A-64077 (Ziluten, 5 mg/kg, p.o.) abolished I/R-induced leukotriene synthesis and reduced transluminal protein flux (50%) but did not influence the lumenal accumulation of fluid after I/R. In animals treated with the leukotriene synthesis inhibitor, intestinal vascular resistance significantly declined during the imposed ischemia period and after 60 min of reperfusion. Mucosal myeloperoxidase activity, a biochemical marker for tissue neutrophils, rose significantly after I/R, and these increases were prevented with the 5-lipoxygenase synthesis inhibitor. In other experiments, the lipoxygenase inhibitor nondihydroguaretic acid produced similar results to those of A64077. In an attempt to determine the source of mucosal leukotrienes during intestinal I/R, we imposed in vitro ischemia and reperfusion on normal mucosal tissue in a blood-free environment. Mucosal tissue was incubated in Krebs buffer under oxygen for 3 hr to simulate the control condition, under nitrogen for 3 hr to simulate ischemia and under nitrogen for 2 hr followed by oxygen for 1 hr to simulate I/R.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8169854

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Small β2-glycoprotein I peptides protect from intestinal ischemia reperfusion injury.

Authors:  Michael R Pope; Urska Bukovnik; John M Tomich; Sherry D Fleming
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

Review 2.  Membrane lipid interactions in intestinal ischemia/reperfusion-induced Injury.

Authors:  Emily Archer Slone; Sherry D Fleming
Journal:  Clin Immunol       Date:  2014-05-09       Impact factor: 3.969

3.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

4.  Complement Initiation Varies by Sex in Intestinal Ischemia Reperfusion Injury.

Authors:  Miaomiao Wu; Jennifer M Rowe; Sherry D Fleming
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.